GPC2-CAR T cells for children and young adults with relapsed medulloblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with medulloblastoma or another similar type of brain tumor that has come back or not responded to treatment.
- Your tumor cells tested positive for a protein called GPC2.
- You are between 12 months and 30 years old.
- You have disease that can be measured on scans or in spinal fluid.
- Your organs (kidneys, liver, heart, lungs) and bone marrow are working well enough.
- You are not pregnant, and if you could have children, you agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
This trial tests a new type of immune therapy (CAR T cells) that targets a protein called B7-H3 found on some brain tumors. It is for children and young adults with certain brain or spinal cord tumors that have come back after standard treatment, and aims to see if the treatment is safe and effective.
This Phase 1 study tests a custom immune therapy called GD2 CAR T cells in children and adults with a specific type of diffuse midline glioma (DMG) that has the H3K27M mutation. The goal is to see if the treatment is safe and can help control the cancer.
This trial tests a new treatment using engineered immune cells (CAR T cells) that target a protein called GPC2 found on some cancer cells. It is for patients with high-risk neuroblastoma or metastatic retinoblastoma that has returned or not responded to other treatments.
This trial tests a new type of immunotherapy called CAR T cells—immune cells engineered in the lab to fight a specific brain tumor called ATRT (atypical teratoid rhabdoid tumor). The cells are designed to recognize and attack tumor cells that have a protein called GPC3, and are enhanced with immune-boosting signals to work better.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.